Completed PHASE4 INTERVENTIONAL 2-arm NCT01119261

EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol (EU-PACT)

Sponsor: Democritus University of Thrace

Conditions Atrial Fibrillation Venous Thromboembolism

Interventions Genotype-guided dosing algorithm Non-genotype-guided dosing algorithm

Updated 5 times since 2017 Last updated: Jun 17, 2013 Started: Nov 30, 2010 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Atrial Fibrillation and Venous Thromboembolism and is currently completed. Democritus University of Thrace leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Democritus University of Thrace
Elisabethinen Hospital
Erasmus Medical Center
LGC Limited
Leiden University Medical Center
Newcastle University
University of Liverpool
University of Ulm
Uppsala University
Utrecht Institute for Pharmaceutical Sciences
Utrecht University

Data source: Utrecht Institute for Pharmaceutical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Alexandropoulis, Greece
• Utrecht, Netherlands